A biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug entities based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders.


Updates from The Motley Fool

Latest updates on Hemispherx BioPharma from Fool.com.


Stock Performance

HEB vs. S&P 500 | 2 Year Performance
View Interactive HEB Charts
Sponsored by

Key Data Points

Primary metrics and data points about Hemispherx BioPharma.
Current Price: $1.26
Prev Close: $1.26
Open: $1.25
Bid: $1.01
Ask: $1.37
Day's Range: $1.25 - $1.28
52wk Range: $0.72 - $2.64
Volume: 24,658
Avg Vol 239,274
Market Cap: $312M
P/E (ttm): -1.31
EPS (ttm): ($0.96)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Hemispherx BioPharma.
CAPS Rating 1 out of 5
 
107 Outperform
82 Underperform
CAPS All Stars
 
15 Outperform
35 Underperform

How do you think Hemispherx BioPharma will perform against the market?



You pick for Hemispherx BioPharma is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Thomas K. Equels, CEO

0% Approve

Based on 1 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Hemispherx BioPharma.

A biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug entities based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders.

  • Exchange: NYSEMKT
  • Sector: Healthcare
  • Industry: Drug Makers